Stemline Therapeutics Inc (STML.O)

STML.O on Consolidated Issue listed on NASDAQ Capital Market

15.08USD
30 Mar 2015
Change (% chg)

-- (--)
Prev Close
$15.08
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
207,415
52-wk High
$21.28
52-wk Low
$10.50

STML.O

Chart for STML.O

About

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk. The Company is developing two clinical-stage product candidates, SL-401 and SL-701. The indication for SL-401 is a targeted therapy directed to the interleukin... (more)

Overall

Beta: --
Market Cap(Mil.): $268.72
Shares Outstanding(Mil.): 17.82
Dividend: --
Yield (%): --

Financials

  STML.O Industry Sector
P/E (TTM): -- 137.41 40.78
EPS (TTM): -2.23 -- --
ROI: -42.31 -0.59 16.19
ROE: -42.70 -2.32 17.04
Search Stocks

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,968 -20.50
Eisai Co., Ltd (4523.T) ¥8,535 -263.00
Sumitomo Dainippon Pharma Co Ltd (4506.T) ¥1,424 -16.00
Pfizer Inc. (PFE.N) $35.00 +0.47
Novartis AG (NOVN.VX) CHF97.25 -0.60
Merck & Co., Inc. (MRK.N) $58.34 +0.59
Roche Holding Ltd. (ROG.VX) CHF270.10 +5.10
Sanofi SA (SASY.PA) €92.83 +0.13
GlaxoSmithKline plc (GSK.L) 1,574.00p -10.50
Amgen, Inc. (AMGN.OQ) $164.30 --

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks